The latest information about BioMark Diagnostics to keep you up to date.
BioMark Diagnostics is leading the world in early-stage cancer detection with an oncology focus designed to improve patient outcomes.
Vancouver, British Columbia – (August 30th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE:
JAPAN PATENT OFFICE (JPO) ISSUED BIOMARK PATENT WITH CLAIMS COVERING ITS LUNG CANCER URINE BASED
BIOMARK Unveils SIGNIFICANT Scientific Advancements from its Leading liquid bioPSY TECHNOLOGY at ASCO 2023 Annual
Biomark’s Dr. Maksymuik Presents at Prestigous ASCO Annual Meeting Biomark Diagnostics, an early stage cancer
The new family of patent granted by USPTO strengthens BioMark’s global intellectual property position in
BIOMARK LATEST RESULTS ACCEPTED FOR PRESENTATION at the American Society of Clinical Oncology (ASCO) Annual
BIOMARK PRESENTS NOVEL LIQUID BIOPSY DATA IN PULMONARY NEUROENDOCRINE TUMORS Vancouver, British Columbia – (March
BIOMARK PROVIDES THIRD QUARTER OPERATIONAL UPDATE AND 2023 Vancouver, British Columbia – (March 1st, 2022)
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2
Rashid A. Bux (CEO)
[email protected]